Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression
Summary Background : Insufficient acid suppression is one of the main causes of proton pump inhibitor‐refractory gastro‐oesophageal reflux disease. Aim : To achieve more potent and long‐lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genoty...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2004-01, Vol.19 (1), p.113-122 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122 |
|---|---|
| container_issue | 1 |
| container_start_page | 113 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 19 |
| creator | Shimatani, T. Inoue, M. Kuroiwa, T. Horikawa, Y. |
| description | Summary
Background : Insufficient acid suppression is one of the main causes of proton pump inhibitor‐refractory gastro‐oesophageal reflux disease.
Aim : To achieve more potent and long‐lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status.
Methods : In a cross‐over study, 18 healthy Helicobacter pylori‐negative males (six homozygous extensive metabolizers, six heterozygous extensive metabolizers and six poor metabolizers) were given rabeprazole 10 mg once daily, 20 mg once daily or 10 mg twice daily, or water only (baseline data), for 7 days each. On day 7 of each regimen, 24‐h intragastric pH‐metry was performed.
Results : No significant differences were observed in median pH values and pH > 4 holding time ratios between rabeprazole 10 mg once daily and 20 mg once daily. However, with rabeprazole 10 mg twice daily, these parameters were significantly higher than those with 20 mg once daily. The potency of acid suppression by rabeprazole was influenced by the CYP2C19 genotype status. The differences were somewhat significant but not large. The incidence of nocturnal acid breakthrough was lowest with rabeprazole 10 mg twice daily.
Conclusions : Rabeprazole 10 mg twice daily, not 20 mg once daily, should be administered to achieve more potent and long‐lasting acid suppression. |
| doi_str_mv | 10.1046/j.1365-2036.2003.01821.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71566894</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71566894</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5111-7d33bf91a058d30b7905cdec51cbca028836d23ac10771196e897ff57ec0e5f43</originalsourceid><addsrcrecordid>eNqNkMtu1DAUhi0EokPhFZA3sEs4tseXLFhUFZRKlUCorC3HORk85IadUTtdVeoL9Bn7JE2YqN2yOpb-7z_H-gihDHIGa_VpmzOhZMZBqJwDiByY4Sy_fkFWT8FLsgKuiowbJo7Im5S2AKA08NfkiK2V0UyLFfnz05U4RHfTNzitf7i9azd0vAoeaeVCs6ch0bQbMIY-0rGnfEH67omop6QLm9_jw-39GFqkG5fGGDx1PlRzeYiYUui7t-RV7ZqE75Z5TH59_XJ5-i27-H52fnpykXnJGMt0JURZF8yBNJWAUhcgfYVT6EvvgBsjVMWF8wy0ZqxQaApd11KjB5T1WhyTj4e9Q-z_7jCNtg3JY9O4DvtdsppJpUwxg-YA-tinFLG2Qwyti3vLwM6i7dbOPu3s086i7T_R9nqqvl9u7MoWq-fiYnYCPiyAS941dXSdD-mZk5IrbfjEfT5wV6HB_X9_wJ78uJxf4hG_h5vW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71566894</pqid></control><display><type>article</type><title>Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Shimatani, T. ; Inoue, M. ; Kuroiwa, T. ; Horikawa, Y.</creator><creatorcontrib>Shimatani, T. ; Inoue, M. ; Kuroiwa, T. ; Horikawa, Y.</creatorcontrib><description>Summary
Background : Insufficient acid suppression is one of the main causes of proton pump inhibitor‐refractory gastro‐oesophageal reflux disease.
Aim : To achieve more potent and long‐lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status.
Methods : In a cross‐over study, 18 healthy Helicobacter pylori‐negative males (six homozygous extensive metabolizers, six heterozygous extensive metabolizers and six poor metabolizers) were given rabeprazole 10 mg once daily, 20 mg once daily or 10 mg twice daily, or water only (baseline data), for 7 days each. On day 7 of each regimen, 24‐h intragastric pH‐metry was performed.
Results : No significant differences were observed in median pH values and pH > 4 holding time ratios between rabeprazole 10 mg once daily and 20 mg once daily. However, with rabeprazole 10 mg twice daily, these parameters were significantly higher than those with 20 mg once daily. The potency of acid suppression by rabeprazole was influenced by the CYP2C19 genotype status. The differences were somewhat significant but not large. The incidence of nocturnal acid breakthrough was lowest with rabeprazole 10 mg twice daily.
Conclusions : Rabeprazole 10 mg twice daily, not 20 mg once daily, should be administered to achieve more potent and long‐lasting acid suppression.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.2003.01821.x</identifier><identifier>PMID: 14687173</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adult ; Antacids - administration & dosage ; Anti-Ulcer Agents - administration & dosage ; Aryl Hydrocarbon Hydroxylases - genetics ; Benzimidazoles - administration & dosage ; Biological and medical sciences ; Circadian Rhythm ; Cross-Over Studies ; Cytochrome P-450 CYP2C19 ; Digestive system ; Gastric Acid - metabolism ; Gastroenterology. Liver. Pancreas. Abdomen ; Genotype ; Helicobacter Infections - complications ; Helicobacter pylori ; Homozygote ; Humans ; Hydrogen-Ion Concentration ; Male ; Medical sciences ; Mixed Function Oxygenases - genetics ; Omeprazole - analogs & derivatives ; Pharmacology. Drug treatments ; Rabeprazole</subject><ispartof>Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (1), p.113-122</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5111-7d33bf91a058d30b7905cdec51cbca028836d23ac10771196e897ff57ec0e5f43</citedby><cites>FETCH-LOGICAL-c5111-7d33bf91a058d30b7905cdec51cbca028836d23ac10771196e897ff57ec0e5f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.2003.01821.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.2003.01821.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15526782$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14687173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimatani, T.</creatorcontrib><creatorcontrib>Inoue, M.</creatorcontrib><creatorcontrib>Kuroiwa, T.</creatorcontrib><creatorcontrib>Horikawa, Y.</creatorcontrib><title>Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background : Insufficient acid suppression is one of the main causes of proton pump inhibitor‐refractory gastro‐oesophageal reflux disease.
Aim : To achieve more potent and long‐lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status.
Methods : In a cross‐over study, 18 healthy Helicobacter pylori‐negative males (six homozygous extensive metabolizers, six heterozygous extensive metabolizers and six poor metabolizers) were given rabeprazole 10 mg once daily, 20 mg once daily or 10 mg twice daily, or water only (baseline data), for 7 days each. On day 7 of each regimen, 24‐h intragastric pH‐metry was performed.
Results : No significant differences were observed in median pH values and pH > 4 holding time ratios between rabeprazole 10 mg once daily and 20 mg once daily. However, with rabeprazole 10 mg twice daily, these parameters were significantly higher than those with 20 mg once daily. The potency of acid suppression by rabeprazole was influenced by the CYP2C19 genotype status. The differences were somewhat significant but not large. The incidence of nocturnal acid breakthrough was lowest with rabeprazole 10 mg twice daily.
Conclusions : Rabeprazole 10 mg twice daily, not 20 mg once daily, should be administered to achieve more potent and long‐lasting acid suppression.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adult</subject><subject>Antacids - administration & dosage</subject><subject>Anti-Ulcer Agents - administration & dosage</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Circadian Rhythm</subject><subject>Cross-Over Studies</subject><subject>Cytochrome P-450 CYP2C19</subject><subject>Digestive system</subject><subject>Gastric Acid - metabolism</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Genotype</subject><subject>Helicobacter Infections - complications</subject><subject>Helicobacter pylori</subject><subject>Homozygote</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Pharmacology. Drug treatments</subject><subject>Rabeprazole</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtu1DAUhi0EokPhFZA3sEs4tseXLFhUFZRKlUCorC3HORk85IadUTtdVeoL9Bn7JE2YqN2yOpb-7z_H-gihDHIGa_VpmzOhZMZBqJwDiByY4Sy_fkFWT8FLsgKuiowbJo7Im5S2AKA08NfkiK2V0UyLFfnz05U4RHfTNzitf7i9azd0vAoeaeVCs6ch0bQbMIY-0rGnfEH67omop6QLm9_jw-39GFqkG5fGGDx1PlRzeYiYUui7t-RV7ZqE75Z5TH59_XJ5-i27-H52fnpykXnJGMt0JURZF8yBNJWAUhcgfYVT6EvvgBsjVMWF8wy0ZqxQaApd11KjB5T1WhyTj4e9Q-z_7jCNtg3JY9O4DvtdsppJpUwxg-YA-tinFLG2Qwyti3vLwM6i7dbOPu3s086i7T_R9nqqvl9u7MoWq-fiYnYCPiyAS941dXSdD-mZk5IrbfjEfT5wV6HB_X9_wJ78uJxf4hG_h5vW</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Shimatani, T.</creator><creator>Inoue, M.</creator><creator>Kuroiwa, T.</creator><creator>Horikawa, Y.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200401</creationdate><title>Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression</title><author>Shimatani, T. ; Inoue, M. ; Kuroiwa, T. ; Horikawa, Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5111-7d33bf91a058d30b7905cdec51cbca028836d23ac10771196e897ff57ec0e5f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adult</topic><topic>Antacids - administration & dosage</topic><topic>Anti-Ulcer Agents - administration & dosage</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Circadian Rhythm</topic><topic>Cross-Over Studies</topic><topic>Cytochrome P-450 CYP2C19</topic><topic>Digestive system</topic><topic>Gastric Acid - metabolism</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Genotype</topic><topic>Helicobacter Infections - complications</topic><topic>Helicobacter pylori</topic><topic>Homozygote</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Pharmacology. Drug treatments</topic><topic>Rabeprazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimatani, T.</creatorcontrib><creatorcontrib>Inoue, M.</creatorcontrib><creatorcontrib>Kuroiwa, T.</creatorcontrib><creatorcontrib>Horikawa, Y.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimatani, T.</au><au>Inoue, M.</au><au>Kuroiwa, T.</au><au>Horikawa, Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2004-01</date><risdate>2004</risdate><volume>19</volume><issue>1</issue><spage>113</spage><epage>122</epage><pages>113-122</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background : Insufficient acid suppression is one of the main causes of proton pump inhibitor‐refractory gastro‐oesophageal reflux disease.
Aim : To achieve more potent and long‐lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status.
Methods : In a cross‐over study, 18 healthy Helicobacter pylori‐negative males (six homozygous extensive metabolizers, six heterozygous extensive metabolizers and six poor metabolizers) were given rabeprazole 10 mg once daily, 20 mg once daily or 10 mg twice daily, or water only (baseline data), for 7 days each. On day 7 of each regimen, 24‐h intragastric pH‐metry was performed.
Results : No significant differences were observed in median pH values and pH > 4 holding time ratios between rabeprazole 10 mg once daily and 20 mg once daily. However, with rabeprazole 10 mg twice daily, these parameters were significantly higher than those with 20 mg once daily. The potency of acid suppression by rabeprazole was influenced by the CYP2C19 genotype status. The differences were somewhat significant but not large. The incidence of nocturnal acid breakthrough was lowest with rabeprazole 10 mg twice daily.
Conclusions : Rabeprazole 10 mg twice daily, not 20 mg once daily, should be administered to achieve more potent and long‐lasting acid suppression.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>14687173</pmid><doi>10.1046/j.1365-2036.2003.01821.x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2004-01, Vol.19 (1), p.113-122 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71566894 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Free Content; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Adult Antacids - administration & dosage Anti-Ulcer Agents - administration & dosage Aryl Hydrocarbon Hydroxylases - genetics Benzimidazoles - administration & dosage Biological and medical sciences Circadian Rhythm Cross-Over Studies Cytochrome P-450 CYP2C19 Digestive system Gastric Acid - metabolism Gastroenterology. Liver. Pancreas. Abdomen Genotype Helicobacter Infections - complications Helicobacter pylori Homozygote Humans Hydrogen-Ion Concentration Male Medical sciences Mixed Function Oxygenases - genetics Omeprazole - analogs & derivatives Pharmacology. Drug treatments Rabeprazole |
| title | Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A40%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rabeprazole%2010%E2%80%83mg%20twice%20daily%20is%20superior%20to%2020%E2%80%83mg%20once%20daily%20for%20night%E2%80%90time%20gastric%20acid%20suppression&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Shimatani,%20T.&rft.date=2004-01&rft.volume=19&rft.issue=1&rft.spage=113&rft.epage=122&rft.pages=113-122&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.2003.01821.x&rft_dat=%3Cproquest_cross%3E71566894%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71566894&rft_id=info:pmid/14687173&rfr_iscdi=true |